Lexicon Pharmaceuticals | LXRX - Sales Revenues


Lexicon Pharmaceuticals reported $5.49M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 12.59B 1.43B Jun/2026
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 22.97B 3.17B Jun/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Illumina USD 1.16B 70M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
J&J USD 25.31B 1.21B Jun/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 109.37M 19.17M Jun/2026
Merck USD 16.6B 310M Jun/2026
Moderna USD 100M 289M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Thermo Fisher Scientific USD 11.99B 980M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024